From: Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Drug Type | Phase | Estimated out-of-pocket clinical costs (in millions of 2013 USD) | Probability of entering phase | Expected out-of-pocket clinical costs (in millions of 2013 USD) | Overall Probability of clinical success | Out-of-pocket clinical cost per approved drug (in millions of 2013 USD) |
---|---|---|---|---|---|---|
Non-orphan | 1 | $2.6 | 100% | $2.6 | 10.44% | $291.4 |
2 | $9.9 | 64.5% | $6.4 | |||
3 | $102.7 | 20.9% | $21.5 | |||
Total | $30.5 | |||||
Orphan | 1 | $3.8 | 100% | $3.8 | 32.93% | $166.1 |
2 | $23.7 | 86.8% | $20.6 | |||
3 | $49.9 | 60.8% | $30.3 | |||
Total | $54.7 |